Plixorafenib

FORE Biotherapeutics has raised $38 million in Series D-2 financing to advance its global Phase 2 FORTE Master Protocol evaluating plixorafenib across multiple BRAF-mutated cancer indications.

Researchers from Sylvester Comprehensive Cancer Center will deliver 9 oral presentations, 4 rapid oral presentations, and 51 poster presentations at the upcoming ASCO 2025 Annual Meeting, showcasing significant advances across multiple cancer types.

FORE Biotherapeutics is advancing plixorafenib in clinical trials targeting BRAF V600-mutated recurrent CNS tumors, rare solid tumors, and solid tumors with BRAF fusions.

FORE Biotherapeutics, a biotherapeutics company focused on developing targeted cancer therapies, has outlined its recent pipeline achievements and key strategic objectives for 2025. The company's CEO, William Hinshaw, will present these developments at the 43rd Annual J.P. Morgan Healthcare Conference. Fore's focus includes the continued development of plixorafenib, a novel BRAF inhibitor, with potential to set new standards in treating BRAF-driven tumors. The company also reported significant progress in its FORTE Master Protocol trials, demonstrating promising safety and efficacy data across various tumor types.